Novogen Announces The Outcome Of A Comprehensive Science Review
SYDNEY, Aug. 31, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) today confirmed its comprehensive scientific review has identified high value opportunities for its ground-breaking technology platforms in areas of unmet patient ne...
Newly Appointed Acting CEO Outlines Immediate Plans for Novogen
SYDNEY, July 30, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) today confirmed it is committed to progressing its ground-breaking technology platforms to Phase 1 clinical trials as soon as practicable and to ensure the Company delivers the bes...
Novogen Appoints Iain Ross as Acting CEO and Re-appoints Him to the Board
SYDNEY, July 22, 2015 /PRNewswire/ -- Novogen Limited (ASX:NRT; NASDAQ: NVGN), a US-Australian drug development company, today announced the appointment to the Board ofIain Ross, an experienced multi-national pharmaceutical and biotechnology executive. Mr Ross, a former director of Novogen Limit...
Anisina Receives Orphan Drug Designation from FDA for Neuroblastoma
SYDNEY, July 16, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited, today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that its chemotherapy candidate drug, Anisina, has been granted Orphan Drug Designation for neuroblasto...
Pre-clinical Studies Suggest Anisina May Improve Chemotherapy Effectiveness in Childhood Cancer
NEW YORK, July 14, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (NRT: ASX; NVGN: NASDAQ), today announced details of an in vivo proof of concept study that demonstrates their lead anti-tropomyosin drug candidate, Anisina, has the potential to improve the effective...
Novogen Announces the Chairman's Address at the Company's General Meeting
SYDNEY, June 24, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) announced today the Chairman's Address at the Company's General Meeting. Full text follows: Dear Shareholders, The Company is in a solid financial position. With $45M in cash, and t...
Anisina on Track to Enter Clinic in 2016
SYDNEY, June 24, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) (Company), announced today that its candidate cytotoxic chemotherapy drug, Anisina, has proved an effective anti-cancer agent in animals, the result of which it no...
Novogen to Present at Bio International Convention Philadelphia 2015
SYDNEY, June 12, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced today that Novogen Group CEO,Graham Kelly, will be presenting at the Bio International Convention 2015 ( BIO) being held at the Pennsylvania Convention Centre, 1101 Ar...
Studies Confirm TRXE-009 Crosses the Blood-brain Barrier
NEW YORK, June 5, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) confirms that a lipid formulation of TRXE-009 dosed intravenously to animals was able to deliver therapeutic concentrations of TRXE-009 to brain tissue. This confirms that the d...
Novogen Expands Board with Two New Appointments
SYDNEY, June 3, 2015 /PRNewswire/ -- Australian-US drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), announced today the appointment of two new non-executive directors to its Board. MrBryce Carmine and MrIan Phillips will extend the Board to 6 members, inclusive of 5...
Novogen Limited Announces Closing of Rights Issue Entitlement Offer and Notice of Shortfall
SYDNEY, June 2, 2015 /PRNewswire/ -- US-Australian drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), announced today the non-renounceable pro-rata rights issue entitlement announced on21 April 2015 (Rights Issue) was completed successfully. The Rights Issue off...
ATM Technology Extended with New Patent Lodgement
NEW YORK, May 28, 2015 /PRNewswire/ -- US-Australian drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), announced today the lodgement with the US Patent Office of a key patent covering a novel family of compounds within the Company's anti-tropomyosin (ATM) drug te...
Novogen to Present at Brain Tumor Biotech Summit 2015
NEW YORK, May 27, 2015 /PRNewswire/ -- US-Australian drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), announced today that it will present at the Brain Tumor Biotech Summit 2015, being held inNew York on May 29, 2015. The venue is the Lennox Hill Hospital, East 76th...
Novogen to Present at the 2015 Marcum Microcap Conference
SYDNEY and NEW YORK, May 26, 2015 /PRNewswire/ -- US-Australian drug discovery
and development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), announced
today that it will present at the2015 Marcum MicroCap Conference
Novogen to Present at Hong Kong Investor Conference
SYDNEY, May 18, 2015 /PRNewswire/ -- US-Australian drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), announced today that company CEO, DrGraham Kelly, will be a presenting company at Asia Biotech Invest 2015May 20-21. The Novogen presentation is at 10.00 am May 20 a...
Anisina Confirmed as Effective Anti-Cancer Agent in Animal Studies
SYDNEY, May 14, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen (NRT:ASX; NVGN: NASDAQ), today announced that it has confirmed that drug candidate, Anisina, is an effective monotherapy against human melanoma in an animal model. The Company announced recently that Anisina was a...
Australian Studies Confirm TRXE-009 Kills Resistant Paediatric Brain Cancer Cells
SYDNEY and SAN DIEGO, May 8, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), in conjunction with Australian paediatric cancer researchers, released key pre-clinical data on experimental cancer drug-candidate, TRXE-009, confirming its potential to...
Novogen Completes the Private Placement of Equity
SYDNEY, April 29, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (NRT: ASX; NVGN: NASDAQ) (Novogen or Company), announced today that it has completed the placement to US institutional investors of 51,750,000 ordinary shares, raising a total of$15,525,000 (before costs)...
Novogen Regains Full Compliance with NASDAQ Listing Rule
SYDNEY, April 28, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) (Company), announced today that it received a letter from NASDAQ informing it that it had regained full compliance with NASDAQ Listing Rule 5550(b) (Listing Rule). In November 2...
Novogen Posts Details on Rights Issue Offering for Shareholders
SYDNEY, April 27, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (NRT: ASX; NVGN: NASDAQ) (Company), announced last week that it lodged a prospectus with ASIC on23 April 2015 relating to its pro rata non-renounceable rights issue (Offering). The prospectus has been pos...
